IMV (Canada) Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
63
- Latest Deal Type
-
M&A
- Financing Rounds
-
11
- Investments
-
2
IMV (Canada) General Information
Description
IMV Inc is a clinical-stage biopharmaceutical company developing a novel class of cancer vaccines based on DPX, its immune-educating technology platform. DPX is designed to inform a specific, coordinated and persistent anti-tumor immune response, that could change the lives of patients with cancer. Its therapeutic candidate, maveropepimut-S (MVP-S), is a DPX-based cancer vaccine that delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in cancers. The company has one reportable and geographic segment.
Contact Information
Website
www.imv-inc.comCorporate Office
- 130 Eileen Stubbs Avenue
- Suite 19
- Dartmouth, Nova Scotia B3B 2C4
- Canada
Corporate Office
- 130 Eileen Stubbs Avenue
- Suite 19
- Dartmouth, Nova Scotia B3B 2C4
- Canada
IMV (Canada) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
IMV (Canada) Comparisons
Industry
Financing
Details
IMV (Canada) Competitors (17)
One of IMV (Canada)’s 17 competitors is PDS Biotechnology, a Formerly VC-backed company based in Princeton, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PDS Biotechnology | Formerly VC-backed | Princeton, NJ | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Mersana Therapeutics | Formerly VC-backed | Cambridge, MA |
IMV (Canada) Patents
IMV (Canada) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024092352-A1 | Compositions that recruit and activate antigen presenting cells | Inactive | 04-Nov-2022 | ||
| AU-2022354218-A1 | Survivin and mage-a9 dual-targeted immunotherapy | Pending | 29-Sep-2021 | ||
| US-20240390468-A1 | Survivin and mage-a9 dual-targeted immunotherapy | Inactive | 29-Sep-2021 | ||
| WO-2023052842-A1 | Survivin and mage-a9 dual-targeted immunotherapy | Inactive | 29-Sep-2021 | ||
| WO-2023052842-A9 | Survivin and mage-a9 dual-targeted immunotherapy | Inactive | 29-Sep-2021 | A61K40/4268 |
IMV (Canada) Signals
IMV (Canada) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
IMV (Canada) Acquisitions (2)
IMV (Canada)’s most recent deal was a Merger/Acquisition with Rhino Resources. The deal was made on 30-Sep-2009.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Rhino Resources | 30-Sep-2009 | Merger/Acquisition | Holding Companies | ||
| Immunotope | 01-Jun-2008 | Merger/Acquisition | Drug Discovery |
IMV (Canada) Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Immunotope | Doylestown, PA | 2002 |
IMV (Canada) FAQs
-
When was IMV (Canada) founded?
IMV (Canada) was founded in 2000.
-
Where is IMV (Canada) headquartered?
IMV (Canada) is headquartered in Dartmouth, Canada.
-
What is the size of IMV (Canada)?
IMV (Canada) has 63 total employees.
-
What industry is IMV (Canada) in?
IMV (Canada)’s primary industry is Biotechnology.
-
Is IMV (Canada) a private or public company?
IMV (Canada) is a Private company.
-
What is the current valuation of IMV (Canada)?
The current valuation of IMV (Canada) is .
-
What is IMV (Canada)’s current revenue?
The current revenue for IMV (Canada) is .
-
How much funding has IMV (Canada) raised over time?
IMV (Canada) has raised $45.6M.
-
Who are IMV (Canada)’s investors?
Altium Capital Management, CTI Life Sciences Fund, Cato BioVentures, First Angel Network, and Fonds de solidarite FTQ are 5 of 8 investors who have invested in IMV (Canada).
-
Who are IMV (Canada)’s competitors?
PDS Biotechnology, Iovance Biotherapeutics, Fate Therapeutics, Sorrento Therapeutics, and Mersana Therapeutics are some of the 17 competitors of IMV (Canada).
-
When was IMV (Canada) acquired?
IMV (Canada) was acquired on 11-Feb-2024.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process